Antidepressants

Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

Retrieved on: 
Friday, May 21, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Clinical research, Mind–body interventions, Selective serotonin reuptake inhibitors, Antidepressants, Sertraline, Placebo, Psychoactive drugs, Health sciences, Medicine, Rebiotix, DDW, REBIOTIX, DDW

RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.

Key Points: 
  • RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo.
  • In addition to these outcomes, RBX2660 provided a relative reduction of recurrence of 29.4% compared to placebo.
  • The majority of treatment emergent adverse events (TEAEs) for RBX2660 were similar to placebo, and mild to moderate in nature.
  • difficile infection is a global public health threat that requires immediate action to halt the unrelenting cycle of recurrence.

Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, NMDA receptor antagonists, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Esketamine, Ketamine, Amyotrophic lateral sclerosis

as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.

Key Points: 
  • as a scientific and clinical advisor for PharmaTher\xe2\x80\x99s clinical research programs involving ketamine as a potential treatment for major depressive disorders and amyotrophic lateral sclerosis (\xe2\x80\x9cALS\xe2\x80\x9d or \xe2\x80\x9cLou Gehrig\xe2\x80\x99s Disease\xe2\x80\x9d).\nMatthew Macaluso, D.O.
  • Professor Macaluso is also the Clinical Director of the UAB Depression and Suicide Center.
  • Matt has extensive experience in conducting clinical studies involving depression, including being a principal investigator of clinical studies involving esketamine which led to an FDA approval.
  • He is also a co-inventor for the novel use of ketamine as a potential treatment for ALS.

Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics

Retrieved on: 
Thursday, May 20, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Healthcare industry

b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.

Key Points: 
  • b'MIAMI, May 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the \xe2\x80\x9cCompany\xe2\x80\x9d), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its KetaDASH subsidiary has commenced data collection for potential patients and partnering clinics.
  • KetaDASH is available to ketamine clinics and qualified patients whose healthcare provider has prescribed it as a treatment.
  • The KetaDASH platform utilizes proprietary software developed by Ehave which allows patients and medical professionals to view detailed reports on the ketamine therapy\xe2\x80\x99s progress.
  • More information on KetaDASH is available at www.ketadash.com .\nKetamine therapy has turned out to be a life-changing alternative to antidepressants for many patients.

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

Retrieved on: 
Monday, May 17, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Hallucinations, Ketamine, Sedatives, Psychedelic drug

The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.

Key Points: 
  • The FDA IND is our first of many we will aim to obtain, and we are one of the few psychedelics-focused biotech companies that have an IND approved by the FDA for a recognized psychedelic drug.
  • The IND paves the way for us to expeditiously evaluate ketamine and other psychedelics via the FDA regulatory pathway in various mental illness, neurological and pain disorders.
  • There is currently no cure for Parkinson\xe2\x80\x99s disease, although some drug combinations are used to treat the disease symptoms.
  • The possible therapeutic effect of low-dose ketamine on LID was noted in a retrospective analysis of PD patients who received ketamine for pain relief.

Braxia Scientific Opens First Ketamine Therapy Clinic in Quebec; Enters Joint Venture with Neurotherapy Montreal, A Leading Brain Injury Solutions Clinic for Adults and Children

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Neuroscience, Clinical medicine, Neurotechnology, Neuropsychology, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Nasal administration, Neurofeedback, Neuromodulation

"\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.

Key Points: 
  • "\nThe new clinic is located within Neurotherapy Montreal\'s state of the art 14,000 square foot facility providing leading mental health and rehabilitation services, more specifically, brain-based solutions for children and adults using the latest neuromodulation and neuroscience technologies.
  • "Since opening our clinics less than 3 years ago, we have administered over 3,000 Intravenous Ketamine Infusionsand over 60 Intranasal Ketamine treatments.
  • Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression.
  • "\nThe clinic is to be operated as a joint venture, owned equally by the Company and NMC.

Leading CBD, gummy manufacturer Global Widget launches Defense Boost line of immune support gummies

Retrieved on: 
Friday, May 7, 2021
Analgesics, Antidepressants, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Naucleeae, CBD, Hemp, Clinical medicine, Medical specialties, Drugs

"We\'ve expanded our in-house gummy manufacturing capacity and capabilities to introduce non-CBD products that specifically help people boost and maintain their immune systems.

Key Points: 
  • "We\'ve expanded our in-house gummy manufacturing capacity and capabilities to introduce non-CBD products that specifically help people boost and maintain their immune systems.
  • "\nFor information on Defense Boost, retailers can visit www.defenseboost.com .\nGlobal Widget, founded in 2016 and headquartered in Tampa, Florida, is a vertically integrated CPG manufacturer, distributor and marketer of CBD and health and wellness products, and a leader in gummy production and packaging.
  • The company is the trusted powerhouse behind the iconic CBD brand Hemp Bombs, along with health and wellness brands, Defense Boost, Mystic Labs and Black Diamond Kratom.
  • With more than 110,000 square feet of facility space and more than 200 employees, Global Widget is one of the nation\'s largest CBD companies and a leading contract manufacturer providing quality products and support services to retailers and distributors worldwide.

Nectar Leaf, A Natural Therapeutics Company Out of Pittsburgh, Pennsylvania, Is Making an Unexpected Splash in the Coffee Market

Retrieved on: 
Thursday, May 6, 2021
Psychoactive drugs, Antidepressants, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Naucleeae, Coffee, Drugs, Clinical medicine

"Going by the motto of \'Nature\'s Fuel\', we\'re committed to advancing the understanding of natural products.

Key Points: 
  • "Going by the motto of \'Nature\'s Fuel\', we\'re committed to advancing the understanding of natural products.
  • The most notable of which being kratom, CBD, coffee, and teas.
  • Integrate coffee into the fast growing herbal supplement and remedies market.\nThe kratom and coffee consumer are often an overlapping consumer and seek out the same benefits from both.
  • "This unique beverage is perfect for the casual coffee lover who wants to spice up their morning routine.

Champignon Brands Changes Name to Braxia Scientific to Reflect the Integration of Ketamine and Psychedelic Clinics and its Research and Development Priorities

Retrieved on: 
Monday, May 3, 2021
Drugs, Psychoactive drugs, Neurochemistry, Antidepressants, General anesthetics, Arylcyclohexylamines, Chloroarenes, Nicotinic antagonists, Ketamine, Forward-looking statement

The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.

Key Points: 
  • The name change reflects the Company\'s commitment to providing access to, and leadership in, setting the standard of care for ketamine treatment in depression through its network of clinics, as well as the Company\'s ketamine and psychedelic derivative research and drug development priorities.
  • Our goal is to improve the access and quality of mental healthcare service to people affected by these disorders in a highly cost-effective manner.
  • All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance are "forward-looking statements.
  • There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/champignon-brands-changes-name-t...\n'

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Psychoactive drugs, Drugs, NMDA receptor antagonists, Glutamate, Molecular neuroscience, Antidepressants, Ionotropic glutamate receptors, NMDA receptor, N-Methyl-D-aspartic acid, Ketamine

The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).

Key Points: 
  • The webcast will be available for 90 days after the presentation.\nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD).
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada\' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021

Retrieved on: 
Tuesday, April 27, 2021
Major depressive disorder, Antidepressants, Chloroarenes, Selective serotonin reuptake inhibitors

Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.

Key Points: 
  • Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment.
  • In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo.
  • The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.